United States-based pharmaceutical giant Johnson and Johnson (J&J) has sought approval for its single-shot Covid-19 vaccine in India.
The development comes as another US-based firm Novavax also applied for Drug Controller General of India (DCGI)'s approval for emergency use of its Covid-19 vaccine on Thursday (5 August). Novavax has partnered with the Pune-based Serum Institute of India for manufacturing its vaccine.
In a statement issued on Friday (6 August), the J&J said it submitted its emergency use approval application on Thursday (5 August).
J&J has partnered with the Indian biotech firm Biological E for the production of its vaccine in India.
"This is an important milestone that paves the way to bringing our single-dose COVID-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E. Limited," the company said in a statement.
"Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX facility," it added.
J&J's vaccine developed by Janssen Pharmaceutical Companies of Johnson & Johnson comprises one shot and reportedly found to have 85.4 per cent efficacy against severe disease and 93.1 per cent against hospitalisation, reports Hindustan Times.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.